Avelumab (anti-PD-L1)

製品コードA2015 別名: MSB0010718C

Avelumab (anti-PD-L1) (MSB0010718C) is a fully human IgG1 monoclonal antibody that targets the protein programmed death-ligand 1 (PD-L1). Avelumab exhibits potential antibody-dependent cell-mediated cytotoxicity and is used for the treatment of several kinds of carcinoma. MW=143.8 kDa.

Avelumab (anti-PD-L1)
サイズ 価格(税別) 在庫状況
1mg JPY 44500 国内在庫あり
5mg JPY 146500 国内在庫あり
1mg*5 JPY 146500 お問い合わせ
1mg*25 JPY 445500 お問い合わせ

代表番号: 045-509-1970|電子メール:[email protected]
よく尋ねられる質問

文献中Selleckの製品使用例(1)

カスタマーフィードバック1个实验数据

質量管理及び製品安全説明書

現在のバッチを見る: 純度: 99.99% タンパク質濃度: 3.2mg/ml 内毒素: <1EU/mg
99.99

PD-1/PD-L1阻害剤の選択性比較

生物活性

製品説明 Avelumab (anti-PD-L1) (MSB0010718C) is a fully human IgG1 monoclonal antibody that targets the protein programmed death-ligand 1 (PD-L1). Avelumab exhibits potential antibody-dependent cell-mediated cytotoxicity and is used for the treatment of several kinds of carcinoma. MW=143.8 kDa.
In Vitro
In Vitro

Co-incubating chordoma cells with brachyury-specific CD8+ T cells results in significant upregulation of PD-L1 on the tumor cells, mediated by the CD8+ T cells' IFN-γ production, and increases sensitivity of chordoma cells to avelumab-mediated ADCC. Residential cancer stem cell subpopulations of chordoma cells are also killed by avelumab-mediated ADCC to the same degree as non-cancer stem cell populations. As a monotherapy for chordoma, avelumab may enable endogenous NK cells, while in combination with T-cell immunotherapy, such as a vaccine, avelumab may enhance NK-cell killing of chordoma cells via ADCC.[1]

細胞実験

Objective: Antibody-dependent cellular cytotoxicity assay
Cells: UM-Chor1 cells
Concentrations: 2 μg/mL
Incubation Time: 30 min
Method: To examine the relationship between a CSC subpopulation and ADCC activity, UM-Chor1 cells are left untreated or treated with 50 ng/mL of IFN-γ for 24 h. Cells are then plated as targets at 50,000 cells/well in 6-well round-bottom culture plates and incubated with 2 μg/mL of avelumab at room temperature for 30 min. NK cells are added at 2500,000 cells/well at an E:T ratio of 50:1. After 4 h, tumor cells are harvested and stained with antibodies for flow cytometry.
Reference: https://pubmed.ncbi.nlm.nih.gov/27172898

Avelumab can apply to humanized mice, non-humanized mice (eg: C57BL/6 mice), peripheral blood and other related assays (Only for Reference)

In Vivo
In Vivo

An aggressive, bioluminescent orthotopic bladder cancer model, MB49 tumor cells transfected with luciferase (MB49luc) is used to study the antitumor effects of avelumab. MB49luc bladder tumors are highly positive for the expression of PD-L1 and avelumab administration induces significant (P<0.05) antitumor effects.[2]

動物試験

Objective: Measurement of individual tumors
Animal Models: 16- to 18-week-old female C57BL/6 mice
Formulation: DPBS
Dosages: 400 μg/100 μL
Administration: i.p.
Reference: https://pubmed.ncbi.nlm.nih.gov/26921031/

Avelumab can apply to humanized mice, non-humanized mice (eg: C57BL/6 mice), peripheral blood and other related assays (Only for Reference)

製品説明

CAS No. 1537032-82-8
Formulation PBS buffer, pH 7.2
Isotype Human IgG1
Source Human
Storage
(From the date of receipt)
Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
Shipping Shipped under low temperature conditions
Sterility 5.585

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

大学・企業名を記入してください
名前を記入してください
電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
お問い合わせ内容をご入力ください
Tags: Avelumab (anti-PD-L1)を買う | Avelumab (anti-PD-L1) ic50 | Avelumab (anti-PD-L1)供給者 | Avelumab (anti-PD-L1)を購入する | Avelumab (anti-PD-L1)費用 | Avelumab (anti-PD-L1)生産者 | オーダーAvelumab (anti-PD-L1) | Avelumab (anti-PD-L1)化学構造 | Avelumab (anti-PD-L1)分子量 | Avelumab (anti-PD-L1)代理店